Testosterone Therapy for Women: Benefits, Risks, and Options

Disclosure: This page may contain affiliate or commercial relationships. | Last Updated: August 2026

MEDICAL DISCLAIMER This content is for informational purposes only and does not constitute medical advice. Consult a licensed physician before starting any hormone therapy or treatment.

If you are weighing testosterone therapy for women, the question that likely worries you most is not whether it does anything. It is what it might do to you over the next ten or twenty years, and whether anyone can honestly answer that. The concern is reasonable, and the honest answer is that the evidence supports a much narrower set of uses than the current online conversation suggests, and the long term safety picture is genuinely incomplete.

Most of what has been written about how to increase testosterone was written for men, where formal diagnostic criteria, approved products, and decades of prescribing data all exist. Women are working from a thinner evidence base, no product approved by the US Food and Drug Administration for their use, and a wave of enthusiasm that has outpaced what the clinical trials actually found.

This guide separates those three things. Below is what controlled research supports, what it does not, what the known and unknown risks look like, and the specific questions worth raising with a provider before you commit to anything.

What Testosterone Actually Does in the Female Body

Testosterone is not a male hormone that women happen to carry traces of. It is produced in the ovaries and the adrenal glands, circulates at a small fraction of the concentration seen in men, and acts on tissue throughout the body, either directly through the androgen receptor or after conversion into the more potent androgen dihydrotestosterone, or into estradiol.

That conversion step matters more than most summaries acknowledge. Some of what testosterone appears to do in women may be happening because the body converts it to estrogen first, which makes it harder to attribute any single effect to testosterone on its own.

Levels also change across the lifespan, though not in the way the popular narrative describes. Research using large community samples found that androgen concentrations fall steeply during the early reproductive years, well before midlife, and that natural menopause does not produce an independent drop. A 2025 cross sectional study of Australian women aged 40 to 69 reached a similar conclusion: testosterone concentrations declined from roughly age 40 through the end of the sixth decade and then modestly increased, and the only steroid that tracked with menopausal stage was androstenedione.

The clear exception is surgical. Women who have had both ovaries removed show significantly lower testosterone than postmenopausal women who still have at least one ovary, because the postmenopausal ovary continues producing androgens for years afterward.

There is also no recognized clinical syndrome of testosterone deficiency in women. Presenting at The Menopause Society 2025 Annual Meeting, Susan Davis, who led the international consensus work on this subject, put it plainly: there is no blood level below which testosterone is associated with any particular syndrome or set of symptoms. That single fact shapes almost everything that follows, including why a lab number on its own cannot tell you whether treatment is appropriate.

Why Testosterone Therapy for Women Is Drawing Attention Right Now

Three developments converged. Menopause became a mainstream public conversation rather than a private one. Telehealth made hormone prescribing far easier to access. And social media rewarded a simple, memorable story: that testosterone is the forgotten third hormone, and that women have quietly been denied it.

The prescribing volume reflects that. A 2025 regulatory submission estimated that more than two million off-label testosterone prescriptions are written annually for women in the United States, with compounded preparations accounting for a large additional share. In a single snapshot from July 2025, eighty podcasts on one platform were recommending the treatment to women.

Some of that attention is warranted. There is a real, well documented use case, and there is a real gap in approved products. But the distance between what is promoted and what has been demonstrated in controlled trials is wide, and it is worth understanding before money and hormones change hands. Readers approaching this from a general interest in hormone treatment rather than a specific symptom may find The Complete Guide to TRT in 2026 a useful overview of the wider landscape, though it is oriented primarily toward male treatment.

Understanding the Risks of Female Testosterone Therapy

Risk in this area divides into two categories: effects that have been measured, and effects that have not been studied long enough to measure. Both belong in the decision.

Androgenic side effects

At doses producing premenopausal physiological concentrations, systemic testosterone was associated with mild increases in acne and in body or facial hair growth in some women. Scalp hair loss, clitoral enlargement, and voice change were not associated with physiological dosing in the pooled trial data. 

Those last three are the effects women most often ask about, and they are largely tied to doses that push levels above the female range, which is a central reason guidance is so specific about dosing targets.

Route of administration changes the risk profile

Oral testosterone was associated with unfavorable changes to HDL and LDL cholesterol, and the consensus statement recommends against it. 

Non oral routes, meaning transdermal and injectable preparations at doses approximating physiological female concentrations, showed no statistically significant short term adverse effect on lipid profiles. This is one of the clearest practical distinctions in the guidance, and one worth confirming with any provider proposing an oral product.

Cardiovascular and metabolic signals

Testosterone treatment was not associated with increases in blood pressure, blood glucose, or HbA1c. A nonsignificant trend toward increased deep vein thrombosis risk was observed, though the role of concurrent estrogen therapy could not be excluded. 

Data were insufficient to assess effects on heart attack or death. As noted above, trial populations excluded women already at high cardiometabolic risk, so these reassurances carry limits that should be stated rather than assumed away.

Breast health

Testosterone therapy did not increase mammographic breast density, and available data suggest short term transdermal use does not affect breast cancer risk. Randomized trial data remain insufficient to assess long term breast cancer risk, and there is no evidence supporting testosterone as a breast cancer preventive. 

Women with a prior breast cancer diagnosis were excluded from the HSDD trials, and the consensus panel recommended caution in women with hormone sensitive breast cancer. If that history applies to you, this is a specialist conversation rather than a telehealth intake question.

The risk that is structural rather than pharmacological

Because no product is approved for women in the United States, every prescription involves either a product approved for men used at a small fraction of its intended dose, or a compounded preparation. Compounded products are not subject to the same manufacturing oversight as approved drugs, and content can vary between batches and pharmacies. 

The consensus panel stated that compounded testosterone cannot be recommended for HSDD given the absence of efficacy and safety evidence, unless no authorized equivalent is available, and that where a compounded product is necessary, the pharmacy should meet Good Manufacturing Practice standards for purity and quality.

That structural gap is the single most underappreciated risk in female testosterone therapy. It is not about the molecule. It is about the absence of a regulated product, a validated dose, and a label.

Not sure whether any of this applies to you? A symptom review with a licensed provider is the step that comes before any prescription. You can talk with a licensed provider about your options and get a clearer read on what is actually driving your symptoms.

The Treatment Options Available to Women Today

Transdermal formulations designed for women

One testosterone cream formulated specifically for women has been registered by Australia’s Therapeutic Goods Administration since November 2020, indicated for hypoactive sexual desire dysfunction in postmenopausal women. It has no equivalent approval in the United States. 

In the United Kingdom it has been imported under special licence rather than supplied through the NHS. For patients in the US, this route is generally not accessible.

Off label use of products approved for men

Where no approved female product exists, the consensus panel considered it reasonable to prescribe an approved male formulation off label, provided blood concentrations are kept within the physiological female range. In practice that means using a small fraction of a male dose, which puts real weight on accurate measuring and consistent application. 

Transdermal gels also carry a transfer risk to partners and children through skin contact, which is a practical point worth raising in the consultation rather than discovering later.

Compounded creams and gels

These are widely used, particularly in telehealth and cash pay settings, precisely because no approved option exists. They also sit outside FDA manufacturing oversight, and current guidance treats them as a fallback rather than a first choice. 

If a compounded preparation is what you are offered, the reasonable questions are which pharmacy is producing it, what standards that pharmacy operates to, and whether an authorized alternative was considered first.

Pellets and injections

Guidance here is unusually direct. The consensus panel recommended against any testosterone preparation that produces supraphysiological concentrations, naming pellets and injections specifically. The American College of Obstetricians and Gynecologists reached a similar conclusion, recommending preparations other than pellets for testosterone delivery in women, citing the absence of safety data and the inability to remove a pellet once implanted.

That last point is the operational problem. If levels run too high, there is no way to reduce the dose short of surgical removal, and any androgenic effects persist until the pellet is exhausted. Pellets are frequently marketed as the convenient option, and it is fair to ask whether convenience is the reason they are being recommended to you.

What Testosterone Therapy for Women Typically Costs

Because prescribing for women is off label and often compounded, insurance coverage is uncommon. Most plans exclude compounded medications outright, and coverage for testosterone written outside an approved indication is difficult to obtain even with documentation.

Published estimates for compounded testosterone cream commonly cluster in a range of roughly thirty to eighty dollars per month, although figures vary considerably by pharmacy, concentration, and region, and they change frequently. Laboratory work, provider consultations, and follow up monitoring sit on top of that, and monitoring is not optional if the treatment is being done properly. Subscription programs that bundle labs and visits can look simpler, but they are not automatically cheaper once you account for the repeat levels that guidance calls for.

Treat any specific figure you find online, including the ones above, as a starting point for questions rather than a quote. Our TRT cost guide breaks the components down in more detail, and readers comparing programs on price may find the cheapest online TRT clinics comparison useful. Both are written primarily around male treatment protocols, so the medication costs will not map directly, but the structure of what you are paying for, consultations, labs, medication, and monitoring, is the same.

Cost is also a signal worth reading. A program that prices monitoring as an optional add on has told you something about how it views monitoring.

What to Ask Your Provider Before Starting

Conversations about TRT for women often borrow the framing used for men, which can leave the most important questions unasked. These are worth raising directly, and worth writing down beforehand.

• What specific symptom are we treating, and does it meet the formal definition of hypoactive sexual desire disorder, or is it something else?
• What have we ruled out first: medication side effects, thyroid function, sleep quality, iron status, depression or anxiety, relationship factors, and genitourinary symptoms of menopause?
• Which formulation are you proposing, and why that route rather than a transdermal preparation?
• How will you keep my levels within the physiological female range, and which assay does your laboratory use?
• When will you recheck my level after I start, and how often after that?
• What is our stopping point if I do not notice a benefit?
• Which androgenic effects should I watch for, and which of them may not reverse after stopping?
• Are there treatments approved for this specific indication that we should consider first, and why are we not starting there?
• If you are recommending a compounded product or a pellet, what is the clinical reason for that choice over an alternative?
• Given my personal and family history, particularly of breast cancer or cardiovascular disease, do the trial safety findings actually apply to me?

A provider who welcomes these questions is a good sign. A program that cannot answer the ones about monitoring and stopping rules is telling you something about how it is built.

Practical Next Steps

Start with what is actually bothering you

Write down the specific symptoms, when they started, how much distress they cause, and what else changed around the same time. Distress is not a soft detail here. It is part of the diagnostic definition for the one indication the evidence supports, and it is the thing that separates a treatable condition from a normal shift in desire.

Rule out the reversible contributors first

Sleep disruption, thyroid dysfunction, iron deficiency, depression and anxiety, common medications including some antidepressants and hormonal contraceptives, chronic stress, and the genitourinary symptoms of menopause can all produce the symptoms people attribute to low testosterone. Several are straightforward to identify and treat. Working through them before starting testosterone therapy for women is not a delay tactic, it is the sequence the guidelines describe.

Choose the provider before you choose the treatment

The quality of care in this area varies widely, and the difference usually shows up in monitoring and in willingness to say no. Look for a provider who assesses before prescribing, who uses an accurate assay, who schedules follow up levels, and who has a defined stopping point. Our Best TRT Roundup reviews how different telehealth programs handle evaluation and follow up, which is the part that matters most here, though the platforms covered are oriented mainly toward men and not all of them treat women at all.

Set a trial window and a stopping rule in advance

Agree with your provider, before the first prescription, on what improvement would look like, how it will be assessed, and at what point you stop if it does not appear. Guidance points to six months as the outer limit for that decision. Writing it down in advance protects you from the drift that turns a trial into an indefinite subscription.

Revisit the decision periodically

Because safety data do not extend beyond twenty four months, continuing treatment past that point is a decision made with incomplete information, not a settled default. That does not automatically mean stopping. It does mean the conversation should happen again rather than renewing quietly in the background.

Making an Informed Decision About TRT for Women

The honest summary is narrower than either side of this debate tends to allow. Testosterone therapy for women has one indication supported by strong randomized evidence, hypoactive sexual desire disorder in postmenopausal women, where the benefit is real but moderate. For fatigue, mood, cognition, muscle, bone, and disease prevention, the trials did not find what the marketing claims. 

The measured risks at physiological doses look modest over the short term, while the long term picture is unknown rather than reassuring, and the largest practical risk comes from the absence of an approved, regulated product rather than from the hormone itself.

None of that makes it the wrong choice for every woman. It does mean the decision deserves a proper evaluation, an accurate baseline, a plan for monitoring, and a stopping rule agreed in advance. If a program offers you a prescription without those four things, the problem is the program, not the science.

If you want that kind of structured evaluation, PrescribedRX is one option worth considering. Care is delivered by independently licensed providers through its telehealth partners, laboratory testing is part of the process, and follow up is built into the plan rather than sold separately. Availability varies by state and by treatment, and any prescription is issued at the discretion of the licensed provider following a clinical evaluation.

Ready to Get a Clearer Answer? Speak with a licensed provider about your symptoms, review the appropriate testing, and find out whether treatment is clinically appropriate for you, on your timeline and with no obligation to proceed. Contact PrescribedRX

---

About This Guide

This article was written and reviewed in accordance with our editorial standards. Clinical statements are drawn from the 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women and its supporting meta analysis, the 2021 International Society for the Study of Women’s Sexual Health clinical practice guideline, American College of Obstetricians and Gynecologists clinical consensus guidance, and peer reviewed research and conference proceedings current as of June 2026. Regulatory status, product availability, and pricing information reflect publicly available data as of that date and are subject to change. Content is reviewed by a licensed healthcare professional for clinical accuracy. This guide does not establish a provider patient relationship and is not a substitute for individualized medical advice.

Last Updated: August 2026